Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Curative Treatment of Esophageal Carcinoma - Disease, Diagnostics, Therapy in 2022 Surgical resection remains the gold standard for non-metastatic carcinoma of the lower and middle third of the esophagus. Locally advanced tumors (T3) are pretreated neoadjuvantly (radiochemotherapy) or perioperatively (chemotherapy). A differentiated primary staging and an interdisciplinary case presentation are of essential importance today. The individual risk assessment, the pre-habilitation and the individualized treatment play a major role. Clinically, the further advancement of access minimization - through laparoscopic/thoracoscopic and robot-assisted procedures and the associated reduction of access trauma - as well as the treatment of this entity in high volume centers are clearly in the foreground. For cervical carcinomas definitive radiotherapy is often the better alternative, both for tumor biological reasons and for reasons of the increase in complications during surgery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1024/0040-5930/a001345 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Harnessing biomarkers to guide immunotherapy in esophageal cancer: toward precision oncology.
Clin Transl Oncol
September 2025
Department of Basic Science, College of Medicine, Princess Nourah bint Abdulrahman, University, P.O.Box 84428, 11671, Riyadh, Saudi Arabia.
Esophageal cancer (EC) is one of the most serious health issues around the world, ranking seventh among the most lethal types of cancer and eleventh among the most common types of cancer worldwide. Traditional therapies-such as surgery, chemotherapy, and radiation therapy-often yield limited success, especially in the advanced stages of EC, prompting the pursuit of novel and more effective treatment strategies. Immunotherapy has emerged as a promising option; nonetheless, its clinical success is hindered by variable patient responses.
View Article and Find Full Text PDFThree-year outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma: a real-world retrospective study.
J Gastrointest Surg
September 2025
Department of thoracic surgery, Army Medical Center of PLA, Chongqing, China. Electronic address:
Background: The objective of this study was to evaluate the efficacy, safety, as well as the 3-year survival outcomes of neoadjuvant immunotherapy with chemotherapy (NICT) plus surgery in patients with locally advanced esophageal squamous cell carcinoma (ESCC) in real-world settings.
Methods: We performed a retrospective analysis of patients with locally advanced ESCC who underwent surgery after NICT in our hospital between May 2019 and Mar 2022, with a median follow-up of 37.6 months.
The association of pre-neoadjuvant SUVmax and post-neoadjuvant change in SUVmax on FDG-PET with survival after oesophagectomy for cancer.
J Gastrointest Surg
September 2025
Department of Upper Gastrointestinal and Hepatobiliary Surgery, Royal Prince Alfred Hospital, Sydney, Australia; RPA Institute of Academic Surgery, Sydney, Australia; School of Medicine, University of Sydney, Sydney, Australia; Surgical Outcomes Research Centre (SOuRCe), Sydney, Australia.
Background: 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is currently widely used in staging and re-staging oesophageal cancer after neoadjuvant therapy. The maximal standardized uptake value (SUVmax) is a reproducible parameter that may predict survival. This study aimed to determine the prognostic significance of SUVmax and the change in SUVmax after neoadjuvant treatment (ΔSUVmax) on overall and disease-free survival.
View Article and Find Full Text PDFctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma.
Cell Rep Med
August 2025
Department of Thoracic Surgery, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Shanghai Institute of Thoracic Oncology, Shanghai 200030, China. Electronic address:
The diagnostic accuracy of circulating tumor DNA (ctDNA) for detecting molecular residual disease (MRD) after multimodal treatment remains unclear. In a prospective cohort of 132 patients with locally advanced esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant chemoradiotherapy (nCRT) followed by clinical response evaluation and surgery, tumor-informed personalized-panel and fixed-panel ctDNA assays are applied to serial blood samples. Personalized ctDNA assay demonstrates a superior baseline detection rate (99.
View Article and Find Full Text PDFPull-down Heller myotomy improves the clinical outcome of advanced sigmoid achalasia.
Surg Endosc
September 2025
Department of Surgery and Experimental Surgery, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Introduction: Esophagectomy was considered the first line for advanced sigmoid (aSg) achalasia (esophageal angulation < 90°), while laparoscopic Heller myotomy (LHM) has a lower percentage of success. The pull-down LHM (PD-LHM) technique has emerged as a promising and more effective rescue therapy to avoid esophagectomy for aSg achalasia. However, the long-term functional results of PD-LHM are inconclusive.
View Article and Find Full Text PDF